April 12, 2011 10:08 ET

Novel Therapies Such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Gout Therapeutics Market

ROCKVILLE, MD--(Marketwire - Apr 12, 2011) - has announced the addition of GBI Research's new report "Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market" to their collection of Pharmaceuticals market reports. For more information, visit

The global gout therapeutics market is a fast growing market. In 2010, the global gout therapeutics market was worth $542.6m in terms of revenue, which is forecast to grow to $1,561.3m by 2017, showing a growth rate of 16.3% between 2010 and 2017. The prevalence of gout has been increasing continuously since 2002. Consequently, the gout therapeutics market has been growing at a rapid pace over the years, and is expected to accelerate in the coming years. Furthermore, the launch of expected blockbuster drugs such as TMX 67 and Krystexxa, along with the presence of a few promising biologics in the late drug development stage, would drive this growth. As a result, the market will continue to remain fast growing, thereby attracting major pharmaceutical companies to this therapy area.

The number of gout patients is increasing year on year, and currently there are only three approved drugs in the market - Colcrys (colchicine), TMX 67 (febuxostat) and Krystexxa (pegloticase). Better efficacy and safety profiles of these drugs over generics such as non-steroidal anti inflammatory drugs (NSAID), corticosteroids, allopurinol and probenecid create a remarkable scope for gout therapeutics in the future. There is a sharp increase in the number of patients who are unable to respond to the conventional treatment for chronic gout. Therefore Krystexxa could target a more focused patient pool, refractory to conventional allopurinol therapy, thereby providing a better alternative biologic treatment option.

In the past five to six years many pharmaceutical companies have improved their product profiles with respect to the musculoskeletal disorders therapeutics market. This is due to strategic deals with the aim of introducing new products with better efficacy and safety profiles into the market. Many pharmaceutical companies have either acquired or signed licensing deals with companies possessing potential products for the gout therapeutics market. The acquisitions of worldwide rights of Pegsiticase from EnzymeRx by 3SBio, and the pharmaceutical products portfolio from AstraZeneca by BioPhausia, have been the major acquisitions in the gout therapeutics market.

Under licensing agreements the highest valued deal was a licensing agreement between XOMA Ltd and Les Laboratoires Servier to develop and commercialize XOMA 052. In addition, Menarini Group has entered into a licensing agreement with Ipsen to market Adenuric (febuxostat) in 41 countries including Europe, Russia, and countries west of Russia. These strategic consolidations have allowed pharmaceutical companies such as Ipsen Pharmaceuticals, Menarini Group, 3SBio and XOMA Ltd to enter the market.

For more information, visit

Contact Information

  • Contact:
    Veronica Franco
    Email Contact